Examining concerns regarding FDA's proposed changes to generic drug labeling :  hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 1, 2014. 

 - v, 146 pages ;  24 cm 
<br/><br/> Shipping list no.: 2016-0177-M.  Paper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  "Serial No. 113-132."  CRDP Project record. 
<br/><br/>Includes bibliographical references. 
<br/><br/><br/>Microfiche. <br/>[Washington, D.C.] : <br/>U.S. Government Printing Office, <br/>[2016] <br/>2 microfiches : negative. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Generic drugs--Labeling--United States.<br/>Drugs--Safety regulations--United States.<br/>Warning labels--Government policy--United States.
<br/><br/><label>Index Terms--Genre/Form: </label><br/>Legislative hearings.
<br/><br/><label>LC Class. No.: </label>KF27  / .E553 2014 
<br/><br/><label>GPO Item No.: </label>1019-B-01 (MF) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.C 73/8:113-132 
<br/><br/><label>Report. No.: </label>Serial no. 113-132 (United States. Congress. House. Committee on Energy and Commerce)